查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703348

糖尿病足溃疡生物製剂市场－全球产业规模、份额、趋势、机会和预测（按适应症、最终用户、地区和竞争细分，2020-2030 年）

Diabetic Foot Ulcer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球糖尿病足溃疡 (DFU) 生物製剂市值为 6.5 亿美元，预计到 2030 年将达到 8.8 亿美元，预测期内年复合成长率(CAGR) 为 5.41%。由于糖尿病足溃疡 (DFU) 发病率高且常常引发併发症，它给全世界的医疗保健系统带来了沉重的负担。这些溃疡通常是由于血液循环受损、神经病变和免疫反应减弱引起的，因此透过常规方法治疗特别困难。

市场概览
预测期 2026-2030
2024年市场规模 6.5亿美元
2030年市场规模 8.8亿美元
2025-2030 年复合年增长率 5.41%
成长最快的领域 神经缺血性溃疡
最大的市场 北美洲

生物疗法（例如生长因子、基因疗法和细胞疗法）因其能够增强伤口癒合、最大限度地降低感染风险并减轻进一步的併发症而越来越受到人们的采用。该市场拥有多样化的生物产品组合，包括富血小板血浆 (PRP)、皮肤替代品、干细胞疗法和重组人类生长因子。这些治疗旨在刺激组织再生、加速癒合并减少对截肢等侵入性介入的依赖。

随着医疗专业人员不断认识到生物製剂在糖尿病足溃疡管理中的临床益处，预计对这些疗法的需求将持续增长。然而，生物製剂治疗广泛应用的主要障碍之一是其高昂的成本。这些疗法通常需要复杂的製造流程和复杂的输送系统，导致其昂贵。这对于预算有限的医疗保健提供者和患者来说是一个重大挑战。

关键市场驱动因素

医疗保健产业的扩张

主要市场挑战

治疗费用高昂

主要市场趋势

全球糖尿病盛行率上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球糖尿病足溃疡生物製剂市场的影响

第五章：全球糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依适应症（神经缺血性溃疡、神经性糖尿病足溃疡、缺血性糖尿病足溃疡）
    • 按最终使用者（医院、诊所、门诊手术中心、长期照护机构等）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲糖尿病足溃疡生物製剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球糖尿病足溃疡生物製剂市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Organogenesis Inc.
  • Tissue Regenix Group Plc
  • BioTissue Holdings, Inc.
  • Integra LifeSciences Holdings Corporation
  • MIMEDX Group, Inc.
  • Convatec Inc.
  • Smith & Nephew PLC
  • Stedical Scientific, Inc.
  • Zimmer Biomet Holdings, Inc.
  • GUNZE LIMITED

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28114

Global Diabetic foot ulcer (DFU) biologics market was valued at USD 0.65 billion in 2024 and is projected to reach USD 0.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.41% during the forecast period. DFUs pose a significant burden on healthcare systems worldwide, driven by their high prevalence and the complications they often entail. These ulcers typically result from impaired circulation, neuropathy, and weakened immune response, making them particularly challenging to treat through conventional methods.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 0.65 Billion
Market Size 2030USD 0.88 Billion
CAGR 2025-20305.41%
Fastest Growing SegmentNeuro-ischemic Ulcers
Largest MarketNorth America

Biologic therapies-such as growth factors, gene therapies, and cellular treatments-are increasingly being adopted for their ability to enhance wound healing, minimize infection risks, and mitigate further complications. The market features a diverse portfolio of biologic products, including platelet-rich plasma (PRP), skin substitutes, stem cell therapies, and recombinant human growth factors. These treatments aim to stimulate tissue regeneration, accelerate healing, and reduce the reliance on invasive interventions, such as amputation.

As medical professionals continue to recognize the clinical benefits of biologics in DFU management, the demand for these therapies is anticipated to grow consistently. However, one of the primary obstacles to broader adoption is the high cost associated with biologic treatments. These therapies often require sophisticated manufacturing processes and complex delivery systems, contributing to their elevated pricing. This presents a significant challenge for healthcare providers and patients operating within constrained budgets.

Key Market Drivers

Expansion of the Healthcare Sector

The rising global incidence of diabetes is a major driver of DFU prevalence, with approximately 15% of diabetic patients developing foot ulcers. Currently, the global prevalence of DFUs among adults with diabetes is estimated at 6.3%, with annual incidence rates ranging from 9.1 to 26.1 million cases. Risk factors include long-standing diabetes, poor glycemic control, peripheral neuropathy, and foot abnormalities such as calluses or deformities.

This growing patient population necessitates more effective treatment modalities, including biologics. Ongoing investment in healthcare research and technological innovation is accelerating the development of novel biologic therapies, improving clinical outcomes and enhancing market growth. Notably, AI-powered diagnostic tools and applications are increasingly used to support the detection and management of DFUs, further improving efficiency and treatment precision.

Key Market Challenges

High Cost of Treatment

Biologic therapies are derived from living organisms and involve highly regulated, intricate manufacturing processes, including cell cultivation, purification of biologically active substances, and development of engineered tissues. These processes often require specialized infrastructure, advanced equipment, and stringent quality assurance protocols, all of which contribute to increased production costs.

Additionally, the research and development (R&D) required to bring biologic products to market is both time-intensive and capital-intensive. Companies must conduct comprehensive preclinical studies and clinical trials to validate product safety and efficacy, as well as navigate complex regulatory pathways. These high development costs are ultimately reflected in the pricing of biologic treatments, posing financial challenges for both healthcare systems and patients.

Key Market Trends

Rising Global Diabetes Prevalence

The incidence of diabetes has increased dramatically over recent decades, particularly in low- and middle-income countries where healthcare access remains limited. The global diabetic population surged from 200 million in 1990 to 830 million by 2022. In 2021 alone, diabetes and its related complications-including kidney disease-accounted for over 2 million deaths. Elevated blood glucose levels were also responsible for approximately 11% of all cardiovascular-related fatalities.

This rising prevalence has directly contributed to an increase in DFU cases, creating greater demand for effective, advanced treatment solutions such as biologics. The DFU biologics market is witnessing robust growth, driven by increasing disease incidence and the expanding availability of innovative therapies. Biologic treatments, particularly those utilizing growth factors and cell-based therapies, are gaining widespread adoption due to their superior efficacy in wound healing and infection control.

Key Market Players

  • Organogenesis Inc.
  • Tissue Regenix Group Plc
  • BioTissue Holdings, Inc.
  • Integra LifeSciences Holdings Corporation
  • MIMEDX Group, Inc.
  • Convatec Inc.
  • Smith & Nephew PLC
  • Stedical Scientific, Inc.
  • Zimmer Biomet Holdings, Inc.
  • GUNZE LIMITED

Report Scope

In this report, the Global Diabetic Foot Ulcer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Foot Ulcer Biologics Market, By Indication:

  • Neuro-ischemic Ulcers
  • Neuropathic Diabetic Foot Ulcer
  • Ischemic Diabetic Foot Ulcer

Diabetic Foot Ulcer Biologics Market, By End User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Long-Term Care Settings
  • Others

Diabetic Foot Ulcer Biologics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Foot Ulcer Biologics Market.

Available Customizations:

Global Diabetic Foot Ulcer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Diabetic Foot Ulcer Biologics Market

5. Global Diabetic Foot Ulcer Biologics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Neuro-ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer)
    • 5.2.2. By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Diabetic Foot Ulcer Biologics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By End User
    • 6.3.2. Mexico Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By End User
    • 6.3.3. Canada Diabetic Foot Ulcer Biologics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By End User

7. Europe Diabetic Foot Ulcer Biologics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Diabetic Foot Ulcer Biologics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By End User

8. Asia Pacific Diabetic Foot Ulcer Biologics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By End User
    • 8.3.2. India Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By End User
    • 8.3.3. South Korea Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By End User
    • 8.3.4. Japan Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Diabetic Foot Ulcer Biologics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By End User

9. South America Diabetic Foot Ulcer Biologics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Diabetic Foot Ulcer Biologics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By End User

10. Middle East and Africa Diabetic Foot Ulcer Biologics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Diabetic Foot Ulcer Biologics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetic Foot Ulcer Biologics Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Organogenesis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Tissue Regenix Group Plc
  • 15.3. BioTissue Holdings, Inc.
  • 15.4. Integra LifeSciences Holdings Corporation
  • 15.5. MIMEDX Group, Inc.
  • 15.6. Convatec Inc.
  • 15.7. Smith & Nephew PLC
  • 15.8. Stedical Scientific, Inc.
  • 15.9. Zimmer Biomet Holdings, Inc.
  • 15.10. GUNZE LIMITED

16. Strategic Recommendations

17. About Us & Disclaimer